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Antimicrobial evaluationAbstract Two series of 2,4 thiazolidinedione derivatives (T1–T4) and (T5–T8) containing substi-
tuted imidazoles and one series of 5-substituted 2,4-thiazolidinedione derivatives (T9–T12) were
designed and synthesized. The chemical structures of all the three series of 2,4 thiazolidinedione
derivatives have been elucidated by spectral studies (IR, 1H NMR, 13C NMR and Mass spectra).
The compounds were screened for their anti-bacterial activity against Staphylococcus aureus
ATCC-9144, Staphylococcus epidermidis ATCC-155, Escherichia coli ATCC-25922, Pseudomonas
aeruginosa ATCC-2853 bacterial species and antifungal activity against Aspergillus niger ATCC-
9029, Aspergillus fumigatus ATCC-46645 by the paper disc diffusion technique. The minimum
inhibitory concentrations (MICs) of the compounds were also determined by the agar streak dilu-
tion method. Among the synthesized compounds methyl-2-(4-((3-(2-methoxy-2-oxoethyl)-2,4-
dioxothiazolidine-5-ylidene) methyl)-1H-imidazol-1-yl) acetate (T2), methyl-2-(5-((1-(2-(4-ﬂuor-
ophenylthio)ethyl)-1H-imidazol-4-yl)methylene)-2,4-dioxo thiazolidin-3-yl)acetate (T4) and
methyl-2-(2-((3-(2-methoxy-2-oxoethyl)-2,4-dioxothiazolidine-5-ylidene) methyl)-1H-imidazol-1-yl)
acetate (T8) were found to possess moderately potent antimicrobial activity with MIC of 1.9, 1.4,
1.6, 0.56, 8.8, 2.3 lg/ml (T2), 3.8, 2.2, 1.6, 2.8, 7.9, 1.7 lg/ml (T4) and 2.7, 3.39, 3.2, 1.4, 8.2,
3.4 lg/ml (T8) against the above mentioned respective strains. All other compounds had shown mild
to moderate antibacterial and antifungal activities.
ª 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The introduction of antibiotics in the 1940s was thought to
have eliminated the scourge of all infectious diseases.
However, due to the widespread use and misuse of antibiotics,
bacterial resistance to antibiotics has become a serious publicArabian
2 P. Moorthy et al.health problem. Some of these resistant strains, such as vanco-
mycin-resistant enterococci (VRE) and multidrug resistant
Staphylococcus aureus (MRSA) are capable of surviving the
effects of most, if not all, antibiotics currently in use
(Hooper, 2001; Galimand et al., 2003; Tenover, 2001;
Leclercq and Courvalin, 2002). With the increase in resistance
of bacteria to antibiotic treatment, attention has focused on
developing novel approaches to antimicrobial therapy
(Nagano et al., 2000; Capobianco et al., 2000; Choudhry
et al., 2003; Oliva et al., 2003). The search of new antimicrobial
agents with reduced toxicity and lower side effects is of contin-
uous process. One of the most frequently encountered hetero-
cycles in medicinal chemistry, thiazolidinedione and its
derivatives were reported to possess diverse biological applica-
tions including anti-microbial activities (Brown et al., 1956;
Lima et al., 1992; Tuncbilek and Altanlar, 1999; Bozdag-
Dundar et al., 2006, 2007). The literature survey revealed that
the presence of the substituted aromatic ring at position 5 as
well as substituent like methyl ester and phenyl ester groups
at position 3 is a necessary requirement for its medicinal prop-
erties (Rakowitz et al., 2006; Yu Momose et al., 2002). Thiazo-
lidinedione with substitution at 3rd position has been reported
to be associated with antimicrobial properties. In general the
presence of pharmacophores like-NO2, -Br, phenolic -OH, -
Cl is reported to possess anti-microbial activities (Yu
Momose et al., 2002).
These observations led to the conception that a series of
novel aryl thiazolidinediones can be synthesized by taking
imidazole as well as substituted benzylidene moieties as the
aromatic linker at the 5th position and certain acetyl substitu-
tions at the 3rd position. Thus the present study is designed
accordingly to synthesize various imidazole and substituted
benzylidene derivatives of 2,4 TZDs using respective aromatic
aldehydes by condensation and their chemical structures be
conﬁrmed by IR, 1H NMR and Mass spectral data. Further
to evaluate the antimicrobial potential of the planned com-
pounds they were designed to screen for their anti-bacterial
activity against two Gram-positive bacteria (S. aureus
ATCC-9144, Staphylococcus epidermidis ATCC-155), two
Gram-negative bacteria (Escherichia coli ATCC-25922, Pseu-
domonas aeruginosa ATCC-2853) and anti-fungal (Aspergillus
niger ATCC-9029 and Aspergillus fumigatus ATCC-46645)
activities by the paper disc diffusion technique. The minimum
inhibitory concentrations (MICs) of the compounds can be
determined by the agar streak dilution method.2. Experimental
2.1. Measurements
Melting Points were taken in a Buchi-545 apparatus and are
uncorrected. Infra-red Spectrum was recorded on a Nicolet
6700 FT-IR spectrophotometer using direct Pellets. Proton
Nuclear Magnetic Resonance spectrum was recorded on a Bru-
ker-DPX-400 MHz spectrophotometer. Liquid Chromatogra-
phy–Mass Spectrum (LC–MS) was recorded on Agilent 1200
(Liquid Chromatography), Agilent 6320 (Quadrupole Mass
Analyzer) spectrophotometer. Thin Layer Chromatography
was performed using aluminium plates precoated with Silica
gel 60F254 [E-Merck]. Spots were visualized in the ultraviolet
light chamber, Iodine chamber, potassium permanganatePlease cite this article in press as: Moorthy, P. et al., Synthesis, characterization an
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chromatography was performed by using silicagel (200–400
mesh, Merck) with the indicated solvent system.
2.2. Synthesis
2.2.1. Synthesis of 5-((1H-imidazol-4-yl) methylene)
thiazolidine-2,4-dione (T1)
2,4-Thiazolidinedione (8.538 mmol) was charged in a 50 ml
round bottom ﬂask (RBF) containing toluene (10 ml) and stir-
red well. Imidazole 4-carbaldehyde (8.538 mmol) was charged
and stirred well. Piperidine (1.281 mmol) and benzoic acid
(1.111 mmol) were charged in a stirring condition. The RBF
was kept in the preheated oil bath, temperature was maintained
at 120–130 C and reﬂuxed for a period of 4 h (reaction was
monitored by Thin Layer Chromatography (TLC) with contin-
uous removal of water using Dean–Stark apparatus. Reaction
mixture was cooled to room temperature, ﬁltered using vac-
uum, residue was washed with toluene 3–4 times and then dried
over vacuum. This crude product was puriﬁed by column chro-
matography in the solvent system dichloromethane and meth-
anol (95:5). Yield: 85.2%, RT value (HPLC): 2.268
(acetonitrile: 0.1% formic acid in water), melting point: 276–
278 C, I.R. (direct) cm1: 1609, 1118, 1162, 2930, 1408, 1H
NMR (DMSO-d6) d: 7.65 (1H, s), 7.75 (1H, s), 7.90 (1H, s),
12.13 (1H, s), 12.65 (1H, s), 13C NMR (DMSO-d6) d: 116.69
(2C), 125.32 (1C), 142.28 (2C), 169.27 (1C), 171.89 (1C), MS
m/z: 196.0 (M+).
Same procedure was followed for the compound T5, T9,
T10, T11, T12.
2.2.2. 5-((1H-imidazol-2-yl) methylene) thiazolidine-2,4-dione
(T5)
Yield: 85.2%, RT value (HPLC): 2.035 (acetonitrile: 0.1% for-
mic acid in water), melting point: 226–228 C, I.R. (direct)
cm1:1166, 2917, 1436, 1745, 1220, 1603, 1H NMR (DMSO-
d6) d: 7.3 (1H, s), 7.46 (2H, d, J= 12.8 Hz) 12.36 (1H, s),
12.81 (1H, s), 13C NMR (DMSO-d6) d: 116.98 (d), 125.86 (s),
131.86 (s), 142.7 (s), 169.7 (s), 172.26 (s), MS m/z: 196.0 (M+).
2.2.3. 5-(4-Fluorobenzylidene) thiazolidine-2,4-dione (T9)
Yield: 88.5%, RT value (HPLC): 4.581 (acetonitrile: 0.1% for-
mic acid in water), melting point: 145–146 C, I.R. (direct)
cm1: 1733, 1557, 1318, 1153, 1230, 2817, 1417, 1H NMR
(DMSO-d6) d: 7.58–7.63 (4H, q), 7.78 (1H, s), 12.65 (1H, s),
13C NMR (DMSO-d6) d: 117.71 (1C) 122.35 (1C), 125.65
(1C) 131.04 (1C), 142.46 (1C), 164.97 (1C), 167.39 (1C),
168.66 (1C), 169.82 (1C), MS m/z: 224.0 (M+).
2.2.4. 5-(4-Chlorobenzylidene) thiazolidine-2,4-dione (T10)
Yield: 89.2%, RT value (HPLC): 4.875 (acetonitrile: 0.1% for-
mic acid in water), melting point: 229.5–230 C, I.R. (direct)
cm1: 1712, 1606, 764, 1163, 1323, 2762, 1399, 1H NMR
(DMSO-d6) d: 7.61 (4H, d), 7.79 (1H, s), 12.67 (1H,s),
13C
NMR (DMSO-d6) d: 124.74 (1C), 129.84 (2C), 130.88 (1C)
132.09 (2C), 132.40 (1C), 135.44 (1C), 167.69 (1C), 168.1
(1C), MS m/z: 238 (M+).
2.2.5. 5-(4-Bromobenzylidene) thiazolidine-2,4-dione (T11)
Yield: 88.9%, RT value (HPLC): 4.518 (acetonitrile: 0.1% for-
mic acid in water), melting point: 266.1–267.2 C, I.R. (direct)d antimicrobial evaluation of imidazolyl thiazolidinedione derivatives. Arabian
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(DMSO-d6) d: 7.61 (2H, d), 7.80 (1H, s), 12.67 (1H, s),
13C
NMR (DMSO-d6) d: 122.08 (1C), 124.84 (1C), 131.26 (2C),
131.97 (2C), 132.05 (1C), 134.05 (1C), 168.1 (1C), 172.12
(1C), MS m/z: 281.8 (M+).
2.2.6. 5-(4-Hydroxy-3,5-dimethylbenzylidene) thiazolidine-2,4-
dione (T12)
Yield: 87.2%, RT value (HPLC): 4.490 (acetonitrile: 0.1% for-
mic acid in water), melting point: 187–190 C, I.R. (direct)
cm1: 1721, 1675, 1141, 1302, 2851, 1410, 3469, 1266, 1H
NMR (sDMSO-d6) d: 2.2 (6H, s), 7.18 (2H, s), 7.61 (1H, s),
9.16 (1H, s), 12.45 (1H, s). 13C NMR (DMSO-d6) d: 16.77
(2C), 124.74 (1C), 129.84 (2C), 130.88 (1C) 132.09 (2C),
132.40 (1C) 135.44 (1C), 167.69 (1C), 168.1 (1C) ppm, MS
m/z: 250.1 (M+).
2.2.7. Synthesis of methyl-2-(4-((3-(2-methoxy-2-oxoethyl)-
2,4-dioxothiazolidin-5-ylidene)methyl)-1H-imidazol-1-
yl)acetate (T2)
To a solution of T1 (0.51 mmol), 10 ml of dimethyl formamide
and sodium hydride (0.51 mmol) portion wise (exothermic
reaction) was added, stirred for 10–20 min until colour changes
to pale brown. Then methyl 2-bromo acetate (1.02 mmol) was
added, stirred for 1 h (reaction was monitored by TLC). Reac-
tion mixture was quenched with ice cubes, extracted with ethyl
acetate (3 volume · 3 times), then washed with water (3 vol-
ume · 3 times) and brine solution (3 volume · 3 times) and
dried over sodium sulphate. It was concentrated under reduced
pressure, after concentration the crude product was puriﬁed by
column chromatography in the solvent system hexane: ethyl
acetate and/or dichloromethane: methanol, then concentrated
to afford the title compound. Yield: 85.2%, RT value (HPLC):
3.503 (acetonitrile: 0.1% formic acid in water), melting point:
185.7–186.3 C, I.R. (direct) cm1: 1614, 1224, 2957, 1409,
1112, 1674, 1H NMR (DMSO-d6) d: 3.69–3.70 (6H, d,
J= 3.72 Hz,), 4.45 (2H, s), 5.09 (2H, s), 7.84 (1H, s), 7.88
(1H, s), 7.91 (1H, s), 13C NMR (DMSO-d6) d: 41.54 (1C),
47.65 (1C), 52.48 (1C), 52.63 (1C), 116.65 (1C), 125.84 (1C),
127.93 (1C) 135.55 (1C), 140.9 (1C), 165.28 (1C), 167.51
(1C), 168.62 (1C), 169.85 (1C), MS m/z: 340.0 (M+).
Same procedure is followed for the compound T7, T8.
2.2.8. Methyl-2-(2-((2,4-dioxothiazolidine-5-ylidene) methyl)-
1H-imidazol-1-yl) acetate (T7)
Yield: 83.6%, RT value (HPLC): 3.217 (acetonitrile: 0.1% for-
mic acid in water), melting point: 177.6–178.5 C, I.R. (direct)
cm1: 1149, 2854, 1443, 1728, 723, 1218, 1665, 1675, 1H NMR
(DMSO-d6) d: 3.69–3.70 (3H, d), 4.44 (2H, s), 7.84–7.88 (2H,
d), 7.95 (1H, s), 12.75 (1H, s), 13C NMR (DMSO-d6) d:
41.49 (1C) 52.61 (1C) 116.02 (1C) 124.32 (1C) 126.19 (1C),
135.43 (1C), 138.3 (1C), 165.33 (1C), 167.53 (1C), 170.00
(1C), MS m/z: 268.0 (M+).
2.2.9. Methyl-2-(2-((3-(2-methoxy-2-oxoethyl)-2,4-
dioxothiazolidine-5-ylidene) methyl)-1H-imidazol-1-yl) acetate
(T8)
Yield: 89.2%, RT value (HPLC): 3.594 (acetonitrile 0.1% for-
mic acid in water), melting point: 167.7–168 C, I.R. (direct)
cm1: 1753, 1557, 1676, 1209, 2957, 1410, 1H NMRPlease cite this article in press as: Moorthy, P. et al., Synthesis, characterization an
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7.33 (1H, s), 7.49 (1H, d), 7.81 (1H, s), 13C NMR (DMSO-
d6) d: 41.61 (1C), 46.81 (1C), 52.54 (1C), 52.67 (1C), 117.71
(1C), 122.35 (1C), 125.65 (1C) 131.04 (1C), 142.46 (1C),
164.97 (1C), 167.39 (1C), 168.66 (1C), 169.82 (1C), MS m/z:
340.0 (M+).2.2.10. Synthesis of 5-((1-(chloroethyl)-1H-imidazol-4-yl)
methylene) thiazolidine-2,4-dione
0.51 mmol of T2 was taken in 10 ml of DMF, stirred well until
formation of clear solution. Sodium hydride (0.51 mmol) was
added portion wise (exothermic reaction), stirred for 10–
20 min, then added 1-bromo 2-chloro ethane (0.51 mmol), stir-
red for 1 h (Reaction is monitored by TLC). Reaction mixture
was quenched with ice cubes, extracted with ethyl acetate (3
volume · 3 times), Then washed with water (3 volume · 3
times) and brine solution (3 volume · 3 times) and dried over
sodium sulphate. It was concentrated under reduced pressure,
after concentration the crude product was puriﬁed by column
chromatography in the solvent used hexane: ethyl acetate, then
concentrated to afford the title compound.
Same procedure was followed for the compound T6.2.2.11. 5-((1-(2-Chloroethyl)-1H-imidazole-2-yl) methylene)
thiazolidine-2,4-dione (T6)
Yield: 60.6%, RT value (HPLC): 3.628 (acetonitrile: 0.1% for-
mic acid in water). melting point: 182.1–183.2 C, I.R. (direct)
cm1: 1136, 2852, 1405, 1607, 723, 1219, 1532, 1667, 1H NMR
(DMSO-d6) d: 3.83–3.86 (2H, t, J= 12 Hz), 3.95–3.98 (2H,
J= 11.92, t), 7.81–7.83 (2H, J= 9.16 Hz, d), 7.95 (1H, s)
12.74 (1H, s), 13C NMR (DMSO-d6) d: 44.57 (1C) 48.68 (1C)
116.73 (1C) 121.9 (1C) 127.69 (1C), 125.32 (1C), 142.28 (1C),
169.27 (1C), 171.89 (1C), MS m/z: 258.0 (M+).2.2.12. Synthesis of 5-((1-(2-(4-ﬂuorophenylthio)ethyl)-1H-
imidazol-4-yl)methylene)thiazolidine-2,4-dione (T3)
7.76 mmol of 4-ﬂuoro benzenethiol was taken and dissolved in
DMF, potassium carbonate was added and stirred for 10–
20 min until colour changes to milky white. Then 7.76 mmol
of 5-((1-(2-chloroethyl)-1H-imidazole-4-yl) methylene) thiazol-
idine-2,4-dione was added, stirred for 1 h (reaction was moni-
tored by TLC), extracted with ethyl acetate (3 volume · 3
times) and then washed with water (3 volume x 3 times) and
brine solution (3 volume · 3 times), and dried over sodium sul-
phate, then concentrated under reduced pressure. After con-
centration the crude product was puriﬁed by column
chromatography using solvent dichloromethane: methanol
(95:5), then the collected product was concentrated to afford
the title compound. Yield: 85.2%, RT value (HPLC): 4.328
(acetonitrile: 0.1% formic acid in water), melting point:
213.4–214.5 C, I.R. (direct) cm1: 1713, 1137, 2848, 1445,
1213, 1602, 1335, 1678, 1H NMR (DMSO-d6) d: 3.34–3.38
(2H, J= 12.92 Hz, t), 4.17–4.20 (2H, J= 12.82 Hz, t), 7.14–
7.19 (2H, J= 17.44 Hz, t), 7.41–7.45 (2H, J= 13.76 Hz, t),
7.58 (1H, s), 7.78 (1H, s), 7.87 (1H, s), 12.16 (1H, s), 13C
NMR (DMSO-d6) d: 41.61 (1C), 52.66 (1C), 117.71 (2C),
119.48 (1C), 122.35 (1C), 125.60 (1C), 131.04 (2C) 132.26
(1C), 141.82 (1C), 142.46 (1C), 164.88 (1C), 168.66 (1C), MS
m/z: 350.0 (M+).d antimicrobial evaluation of imidazolyl thiazolidinedione derivatives. Arabian
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imidazol-4-yl)methylene)-2,4-dioxo thiazolidin-3-yl)acetate
(T4)
Yield: 80.8%, RT value (HPLC): 4.573 (acetonitrile: 0.1% for-
mic acid in water) melting point: 165.8–166.9 C I.R. (direct)
cm1: 1164, 2851, 1401, 1611, 1312, 1220, 1532, 1667, 1H
NMR (DMSO-d6) d: 3.36–3.40 (2H, J= 16.44 Hz, t), 3.70
(3H, s), 4.46 (2H, s), 4.20–4.23 (2H, J= 12.92, t), 7.18–7.21
(2H, J= 17.76 Hz, t), 7.43–7.47 (2H, J= 11.4, t), 7.81 (1H,
s), 7.87 (1H, s), 7.93 (1H, s) ppm, 13C NMR (DMSO-d6) d:
34.71 (1C), 41.92 (1C), 46.24 (1C), 53.02 (1C), 116.8 (2C),
126.18 (1C), 127.32 (1C), 130.25 (1C), 132.36 (2C) 132.47
(1C), 136.06 (1C), 140.69 (1C), 163.24 (1C), 165.67 (1C),
167.93 (1C), 170.32 (1C), MS m/z: 422 (M+).
2.3. Anti-microbial screening
The anti-bacterial activity of the synthesized compounds was
tested against four Gram-positive bacteria (S. aureus ATCC
9144, S. epidermidis ATCC 155, Micrococcus luteus ATCC
4698 and B. cereus ATCC 11778) and three Gram-negative
bacteria (E. coli ATCC 25922 P. aeruginosa ATCC and Kleb-
siella pneumoniae ATCC 11298) using nutrient agar medium
(Hi-Media Laboratories, India). The anti-fungal activities of
the compounds were tested against two fungi namely A. niger
ATCC 9029 and A. fumigatus ATCC using sabouraud dex-
trose agar medium (Hi-Media Laboratories, India).
2.3.1. Paper disc diffusion technique
The sterilized (Gillespie, 1994) (autoclaved at 120 C for
30 min) medium (40–50 C) was inoculated (1 ml/100 ml of
medium) with the suspension (105 cfu ml1) of the microorgan-
ism (matched to McFarland barium sulphate standard) and
poured into a petridish to give a depth of 3–4 mm. The paper
impregnated with the test compounds (lg ml1 in dimethyl
formamide) was placed on the solidiﬁed medium. The plates
were pre-incubated for 1 h at room temperature and incubated
at 37 C for 24 and 48 h for anti-bacterial and anti-fungal
activities, respectively. Ciproﬂoxacin (50 lg/disc) and Keto-
conazole (50 lg/disc) were used as standards for anti-bacterialTable 1 Anti-microbial activity of the synthesized compounds.
Compound In vitro activity – zone of inhibition in m
S. aureus
ATCC 9144
S. epidermidis
ATCC 155
E.
AT
T1 19 (20.1) 19 (17.8) 19
T2 18 (1.9) 16 (1.4) 28
T3 20 (17.5) 25 (18.5) 25
T4 16 (3.8) 18 (2.2) 18
T5 20 (23.7) 23 (21.5) 23
T6 17 (21.5) 20 (21.5) 20
T7 21 (22.1) 27 (22.2) 27
T8 16 (2.7) 18 (3.39) 22
T9 19 (19.2) 24 (20.1) 24
T10 16 (20.1) 22 (20.1) 22
T11 21 (22.1) 25 (22.2) 25
T12 14 (20.0) 18 (20.3) 18
Ciproﬂoxacin (100 lg/disc) 29 (0.2) 31 (0.39) 32
Ketoconazole (100 lg/disc) – – –
Di methyl formamide – – –
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2.3.2. Minimum inhibitory concentration (MIC)
MIC (Hawkey and Lewis, 1994) of the compound was deter-
mined by the agar streak dilution method. A stock solution
of the synthesized compounds (100 lg ml1) in dimethyl form-
amide was prepared and graded quantities of the test com-
pounds were incorporated in speciﬁed quantity of molten
sterile agar (nutrient agar for anti-bacterial activity and sabou-
raud dextrose agar medium for anti-fungal activity). A speci-
ﬁed quantity of the medium (40–50 C) containing the
compound was poured into a petridish to give a depth of 3–
4 mm and allowed to solidify. Suspension of the microorgan-
ism was prepared to contain approximately 105 cfu ml1 and
applied to plates with serially diluted compounds in dimethyl
formamide to be tested and incubated at 37 C for 24 h and
48 h for bacteria and fungi, respectively. The MIC was consid-
ered to be the lowest concentration of the test substance exhib-
iting no visible growth of bacteria or fungi on the plate. The
observed MIC is presented in Table 1.
3. Results and discussion
3.1. Chemistry
In this present investigation a novel series of substituted thia-
zolidinedione compounds were synthesized as per Schemes 1–
3. Scheme 1 illustrates the pathway used for the synthesis of
Imidazole substituted 2,4 TZDs. 5 methylene imidazole
substituted 2,4 TZD (T1) was obtained by treating 1H-imidaz-
ole 4-carbaldehyde with 2,4 thiazolidinedione. T1 with 1-
methyl 2-bromo acetate gives T2, the acetate derivative of
T1 and with 4-ﬂuorobenzene thiol in the presence of sodium
hydride gives chloro ethyl substituted imidazole moiety of
2,4 TZD (T3). Its respective acetate derivative (T4) was syn-
thesized in the presence of 1-methyl 2-bromo acetate.
Scheme 2 shows the reaction between imidazole 2 carbalde-
hyde and 2,4 TZD which gives (T5). T5 forms 1-chloro ethyl
substitution (T6) at imidazole moiety in the presence ofm (MIC in lg/ml)
coli
CC 25,922
P. aeruginosa
ATCC 2853
A. niger
ATCC 9092
A. fumigatus
ATCC 46,645
(22.4) 19 (22.1) 21 (18.2) 20 (20.5)
(1.6) 28 (0.56) 20 (8.8) 26 (2.3)
(15.9) 20 (18.9) 22 (19.2) 19 (18.2)
(1.6) 16 (2.8) 19 (7.9) 18 (1.7)
(22.6) 20 (20.8) 23 (20.7) 18 (21.5)
(22.6) 17 (22.4) 17 (22.7) 17 (22.1)
(21.5) 21 (21.5) 24 (20.7) 20 (22.6)
(3.2) 16 (1.4) 22 (8.2) 26 (3.4)
(17.9) 19 (19.8) 22 (18.6) 15 (17.1)
(18.7) 164 (19.3) 18 (20.7) 18 (21.0)
(21.5) 21 (21.5) 28 (21.6) 25 (21.7)
(19.6) 14 (17.1) 23 (20.6) 15 (21.7)
(0.2) 33 (0.25) – –
– 26 (6.1) 24 (0.23)
– – –
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Synthesis, characterization and antimicrobial evaluation 51-bromo 2-chloro ethane and sodium hydride. Its acetate
derivative at the same position is synthesized by treating with
1-methyl 2-bromo acetate (T7). The diacetate derivative (T8)
of T7 was obtained by treating with 1-methyl 2-bromo ace-
tate. Scheme 3 shows the reaction of various 4 substituted
benzaldehydes with 2,4 TZD to give 4 substituted benzylidene
moieties at the 5th position of 2,4 TZD (substitutions were
ﬂuoro (T9), chloro (T10), bromo (T11), 3,5 dimethyl 4-hydroxy
(T12) derivatives).
The structures of the compounds were characterized by IR,
1H NMR, 13C NMR and Mass spectral data. IR spectra of thePlease cite this article in press as: Moorthy, P. et al., Synthesis, characterization an
Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.08.010compounds showed 2,4 TZD C‚O stretching at 1680–
1760 cm1 and C‚C methylene linkage at 1576–1678 cm1.
In 1H NMR spectra, the imidazole substituted 2,4 TZD com-
pounds showed the methylene linkage proton of 2,4 TZD and
imidazole at 7.5–7.8 ppm as a singlet, imidazole Ar–H protons
as singlet at 7.3–7.8 ppm, acetyl proton at the range 3.5–
5.3 ppm and TZD N–H proton at 12.75 ppm. In 13C NMR
spectra, the acetyl carbons are shown at the range of 40.0–
55.0 ppm, Ar-Carbons at the range of 120–130 ppm, acetyl
C‚O carbons at the range 165–170 ppm. In mass analysis
all the compounds have M+1 ion peaks.d antimicrobial evaluation of imidazolyl thiazolidinedione derivatives. Arabian
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6 P. Moorthy et al.3.2. Biological investigation
All the synthesized compounds were active against all tested
micro-organisms with the range of MIC values for S. aureus
(1.9–23.7 lg/ml), S. epidermidis (1.4–22.2 lg/ml), E. coli
(1.6–22.6 lg/ml), P. aeruginosa (0.56–22.4 lg/ml), A. niger
(7.9–22.7 lg/ml) and A. fumigatus (2.3–24.6 lg/ml). Methyl-
2-(4-((3-(2-methoxy-2-oxoethyl)-2,4-dioxo thiazolidine-5-yli-
dene) methyl)-1H-imidazol-1-yl) acetate T2 was found to
exhibit potent in vitro antimicrobial activity with the MIC of
1.9, 1.4, 1.6, 0.56, 8.8 and 2.3 lg/ml against S. aureus,
S. epidermidis, E. coli, P. aeruginosa, A. niger, A. fumigatus,
respectively. Next to that T4 and T8 compounds exhibited
signiﬁcant antimicrobial activity when compared to the
standard drugs Ciproﬂoxacin and Ketoconazole. Other com-
pounds showed mild to moderate antibacterial and antifungal
activity. The most potent anti-bacterial and anti-fungal activ-
ity exhibited by compound T2 followed by T4 and T8 might
be due to the presence of acetyl substitution at the 3rd position
as well as imidazole moiety at the 5th position of 2,4 TZD.
Moreover, T2 possess the biacetate group one at the 3rd posi-
tion of 2,4 TZD and the other at imidazole nitrogen. The biac-
etate group of T2 might have increased the lipophilic nature of
the molecule which has contributed the efﬁcacy. Similarly p-
chloro and p-ﬂuoro groups on the benzene moiety of the
substituted thiazolidinedione, T9, T10 also exhibited signiﬁcant
anti-microbial activity due to the presence of the p-chloro
group and p-ﬂuoro on the benzylideneamino group of the thia-
zolidinedione moiety.
The anti-microbial activity of the synthesized compounds
may be due to the presence of the versatile pharmacophores
and halogen, which might increase the lipophilic character of
the molecule, which facilitate the crossing through the biolog-
ical membrane of the micro-organism and thereby inhibit their
growth. In conclusion, compounds T2, T4 and T8 could be the
lead compounds for further beneﬁcial modiﬁcation in the
design of thiazolidinedione as an anti-bacterial agent.
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